TY - JOUR T1 - A machine learning explanation of the pathogen-immune relationship of SARS-CoV-2 (COVID-19), model to predict immunity, and therapeutic opportunity JF - medRxiv DO - 10.1101/2020.07.27.20162867 SP - 2020.07.27.20162867 AU - Eric Luellen Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/16/2020.07.27.20162867.abstract N2 - Importance The clinical impacts of this study are it: (1) identified three immunological factors that differentiate asymptomatic, or resistant, COVID-19 patients; (2) identified the levels of those factors that can be used by clinicians to predict who is likely to be asymptomatic or symptomatic; (3) identified a novel COVID-19 therapeutic for further testing; and, (4) ordinally ranked 34 common immunological factors by their importance in predicting disease severity.Objectives The primary objectives of this study were to learn if machine learning could identify patterns in the pathogen-host immune relationship that differentiate or predict COVID-19 symptom immunity and, if so, which ones and at what levels. The secondary objective was to learn if machine learning could take such differentiators to build a model that could predict COVID-19 immunity with clinical accuracy. The tertiary objective was to learn about the relevance of other immune factors.Design This was a comparative effectiveness research study on 53 common immunological factors using machine learning on clinical data from 74 similarly-grouped Chinese COVID-19-positive patients, 37 of whom were symptomatic and 37 asymptomatic.Setting A single-center primary-care hospital in the Wanzhou District of China.Participants Immunological factors were measured in patients who were diagnosed as SARS-CoV-2 positive by reverse transcriptase-polymerase chain reaction (RT-PCR) in the 14 days before the recordation of the observations. The median age of the 37 asymptomatic patients was 41 years (range 8-75 years), 22 were female, 15 were male. For comparison, 37 RT-PCR test-positive patients were selected and matched to the asymptomatic group by age, comorbidities, and sex.Main Outcome The primary study outcome was that asymptomatic COVID-19 patients could be identified by three distinct immunological factors and level: stem-cell growth factor-beta (SCGF-β) (> 127637), interleukin-16 (IL-16) (> 45), and macrophage colony-stimulating factor (M-CSF) (> 57). The secondary study outcome was the novel suggestion that stem-cell therapy with SCGF-β may be a new valuable therapeutic for COVID-19.Results When SCGF-β was included in the machine-learning analysis, a decision-tree and extreme gradient boosting algorithms classified and predicted COVID-19 symptoms immunity with 100% accuracy. When SCGF-β was excluded, a random-forest algorithm classified and predicted COVID-19 asymptomatic and symptomatic cases with 94.8% area under the ROC curve accuracy (95% CI 90.17% to 100%). Thirty-four (34) common immune factors have statistically significant (P-value < .05) associations with COVID-19 symptoms and 19 immune factors appear to have no statistically significant association.Conclusion People with an SCGF-β level > 127637, or an IL-16 level > 45 and M-CSF level > 57, appear to be predictively immune to COVID-19, 100% and 94.8% (ROC AUC) of the time, respectively. Testing levels of these three immunological factors may be a valuable tool at the point-of-care for managing and preventing outbreaks. Further, stem-cell therapy via SCGF-β and/or M-CSF appear to be promising novel therapeutics for COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is in the public domain. ER -